Ultomiris 300 mg/30 mL concentrate for solution for infusion, Soliris 300 mg concentrate for solution for infusion, ALXN 2040
ALXN2040-PNH-303
Phase 3 small_molecule active
Quick answer
Ultomiris 300 mg/30 mL concentrate for solution for infusion, Soliris 300 mg concentrate for solution for infusion, ALXN 2040 for Patients with Paroxysmal Nocturnal Hemoglobinuria is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alexion Europe SAS
- Indication
- Patients with Paroxysmal Nocturnal Hemoglobinuria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active